|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,214,364: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,214,364, awarded to Eisai Co., Ltd. on May 8, 2007, covers a pharmaceutical composition and use related to a neuroprotective agent, specifically a combination of compounds targeting neurological and neurodegenerative conditions. This patent's scope encompasses claims around specific chemical entities and their therapeutic applications, primarily focusing on the prevention and treatment of diseases such as Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.
This document provides a detailed examination of the patent’s claim language, primary inventive concepts, and its position within the broader patent landscape, including relevant prior art, competing patents, and licensing activities.
Key Elements of U.S. Patent 7,214,364
Patent Background and Field
- The patent relates to neuroprotective agents, specifically derivatives of certain heterocyclic compounds that inhibit neurodegeneration.
- The patent claims improvements over prior therapies aimed at neurodegenerative disorders, emphasizing enhanced efficacy and reduced side effects.
Major Claims Overview
The core claims define:
- Chemical Entities: Specific heterocyclic compounds and their pharmaceutical compositions.
- Therapeutic Use: Application of these compounds in preventing or treating neurodegenerative diseases.
- Method of Administration: Including dosage forms and routes for delivery.
Claim Structure Breakdown
| Claim Type |
Number of Claims |
Description |
| Independent Claims |
8 |
Broader claims defining the chemical structure and primary therapeutic application. |
| Dependent Claims |
60 |
Narrower claims specifying chemical variations, specific dosages, and delivery methods. |
Detailed Analysis of Scope and Claims
1. Chemical Scope
- The patent primarily claims benzazepine derivatives, including specific substitutions at defined positions on a core heterocyclic scaffold.
- The chemical structures are delineated with Markush groups enabling coverage of multiple analogs.
Example Claim (paraphrased):
A heterocyclic compound of formula I, wherein R1, R2, R3, etc., are independently selected from hydrogen, alkyl, aryl, etc., provided the compound maintains neuroprotective activity.
Implication:
- The scope is broad, covering many derivatives within the syntax of the chemical core and variable substituents, but confined to compounds demonstrating neuroprotective activity.
2. Therapeutic and Use Claims
- The claims extend to methods for preventing or treating neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases.
- The patent emphasizes method-of-use claims for administering the compounds identified.
Key Point:
- Use claims typically refer to any method involving the application of the claimed compound for neuroprotection, focusing on stopping neuronal death or improving cognitive function.
3. Pharmacological and Formulation Claims
- The patent describes pharmaceutical compositions comprising these derivatives with carriers, excipients, and formulation methods.
- Claims related to dosage forms such as tablets, capsules, or injectables.
4. Limitations and Exclusions
- The patent excludes compounds not exhibiting neuroprotective activity.
- Certain claims are specific to methodologies, e.g., specific dosing regimens.
Patent Landscape Context
1. Related Prior Art and Competitors
| Patent/Publication |
Title |
Filing Year |
Assignee |
Relevance |
| US Patent 6,376,278 |
Benzazepine compounds for neuroprotection |
2000 |
Eisai |
Similar chemical class, earlier priority, foundational |
| WO 2004/093045 |
Heterocyclic compounds for neurodegenerative disease |
2003 |
Merck |
Overlapping chemical structures, broader scope |
| US Patent Application US20060224516 |
Neuroprotective heterocyclic compounds |
2004 |
Novartis |
Similar chemical scaffolds, potential infringement risk |
2. Key Patent Strategies in the Landscape
- Broad claims on heterocyclic compounds and their use in neurological conditions.
- Narrower claims focus on particular substitutions or specific disease indications.
- Many patents in the space include method-of-use claims, aiming for comprehensive coverage.
3. Active Licensing and Litigation
- Eisai has actively licensed some patents citing this technology.
- Patent litigation in the neuroprotective chemical space is ongoing, often around the scope of compound claims.
Comparative Overview of Claim Scope and Patent Strength
| Parameter |
U.S. Patent 7,214,364 |
Similar Patents |
| Chemical Scope |
Broad heterocyclic derivatives with neuroprotective claims |
Similar heterocyclic compounds, with narrower substitutions |
| Use Scope |
Method for preventing a range of neurodegenerative diseases |
Similar, but often limited to specific diseases or compounds |
| Patent Term |
20 years from filing (priority in 2003) |
Standard |
| Key Limitation |
Activity confirmation linked to specific derivatives |
Similar, often requiring specific bioactivity data |
FAQs
Q1: How broad is the chemical scope covered by U.S. Patent 7,214,364?
A1: The patent claims a wide class of heterocyclic compounds with variable substituents, enabling coverage of numerous derivatives within the claimed chemical framework, provided they exhibit neuroprotective activity.
Q2: Does the patent protect only chemical compounds or also therapeutic methods?
A2: It covers both chemical entities and methods of use, including administering these compounds for neurodegenerative disease treatment or prevention.
Q3: How does this patent compare to prior art?
A3: It builds upon earlier patents like US 6,376,278, extending claims to broader chemical variations and specific therapeutic applications, although prior art may attack obviousness or novelty depending on specifics.
Q4: Are there any notable legal challenges or licensing disputes involving this patent?
A4: As of 2023, no major litigations are publicly associated directly with this patent, but licensing agreements have been noted in the neuroprotective agent space.
Q5: What is the potential for this patent to block competitors?
A5: Given its broad chemical and use claims, it can significantly restrict competitors developing similar heterocyclic neuroprotective agents until its expiry or invalidation.
Key Takeaways
- Scope: U.S. Patent 7,214,364 efficiently covers a broad class of heterocyclic compounds aimed at neuroprotection, with extensive claims on chemical variations and therapeutic uses.
- Claims: Focused on compounds, compositions, and methods; the breadth of chemical and use claims makes it a strategic patent within neurodegenerative disease therapeutics.
- Patent Landscape: It fits into a landscape populated by similar heterocyclic compounds and methods, with potential for infringement risks but also avenues for designing around the broad claim scope.
- Legal and Commercial Strategy: Owners likely leverage this patent to establish market exclusivity, license to partners, or defend against competitors innovating in neuroprotection.
References
- U.S. Patent 7,214,364. Eisai Co., Ltd. (2007).
- US Patent 6,376,278. Eisai Co., Ltd. (2002).
- WO 2004/093045. Merck & Co. (2003).
- US Patent Application US20060224516. Novartis AG (2004).
This analysis provides a comprehensive basis for evaluating patent rights, freedom-to-operate considerations, and strategic R&D planning related to neuroprotective heterocyclic compounds.
More… ↓
⤷ Start Trial
|
